Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles

Xunhao Xiong; Rochelle R. Arvizo; Sounik Saha; David J. Robertson; Scott McMeekin; Resham Bhattacharya; Priyabrata Mukherjee

doi:10.18632/oncotarget.2203

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles

Xunhao Xiong, Rochelle R. Arvizo, Sounik Saha, David J. Robertson, Scott McMeekin, Resham Bhattacharya and Priyabrata Mukherjee _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2014; 5:6453-6465. https://doi.org/10.18632/oncotarget.2203

Metrics: PDF 3525 views | HTML 3995 views | ?

Abstract

Xunhao Xiong1,*, Rochelle R. Arvizo2,*, Sounik Saha1, David J. Robertson3, Scott McMeekin4,5, Resham Bhattacharya4,5 and Priyabrata Mukherjee5

1 Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

2 Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, Rochester, MN

3 Department of Chemistry and University of Missouri Research Reactor, University of Missouri, Columbia, Missouri

4 Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

5 Peggy and Charles Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

* These authors contributed equally to this work

Correspondence:

Priyabrata Mukherjee, email:

Keywords: gold nanoparticle; chemoresistance; cancer stem cell; EMT; NF-kappa B

Received: May 22, 2014 Accepted: July 11, 2014 Published: July 11, 2014

Abstract

Recently we reported that gold nanoparticles (AuNPs) inhibit ovarian tumor growth and metastasis in mice by reversing epithelial-mesenchymal transition (EMT). Since EMT is known to confer drug resistance to cancer cells, we wanted to investigate whether anti-EMT property of AuNP could be utilized to sensitize ovarian cancer cells to cisplatin. Herein, we report that AuNPs prevent cisplatin-induced acquired chemoresistance and stemness in ovarian cancer cells and sensitize them to cisplatin. AuNPs inhibit cisplatin induced EMT, decrease the side population cells and key stem cell markers such as ALDH1, CD44, CD133, Sox2, MDR1 and ABCG2 in ovarian cancer cells. Mechanistically, AuNPs prevent cisplatin-induced activation of Akt and NF-kB signaling axis in ovarian cancer cells that are critical for EMT, stem cell maintenance and drug resistance. In vivo, AuNPs sensitize orthotopically implanted ovarian tumor to a low dose of cisplatin and significantly inhibit tumor growth via facilitated delivery of both AuNP and cisplatin. These findings suggest that by depleting stem cell pools and inhibiting key molecular pathways gold nanoparticles sensitize ovarian cancer cells to cisplatin and may be used in combination to inhibit tumor growth and metastasis in ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2203

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles

Abstract